✦ LIBER ✦

A randomized, double-blind, placebo-controlled trial of recombinant human α-interferon therapy for chronic non-A, non-B (type C) hepatitis

✍ Scribed by Di Bisceglie, A.M.; Martin, P.; Kassianides, C.; Goodman, Z.; Lisker-Melman, M.; Banks, S.M.; Hoofnagle, J.H.

Book ID: 122993662
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 576 KB
Volume: 11
Category: Article
ISSN: 0168-8278
DOI: 10.1016/0168-8278(90)90161-J

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis

✍ Masao Omata; Yoshimi Ito; Osamu Yokosuka; Fumio Imazeki; Masami Tagawa; Susumu T 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 527 KB

Recombinant human α-interferon in patien

Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France

✍ Patrick Marcellin; Nathalie Boyer; Emile Giostra; Claude Degott; Anne Marie Cour 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

We have conducted a multicenter randomized controlled trial comparing two doses of recombinant human a-interferon for efficacy in 60 patients with chronic non-A, non-B hepatitis. The source of infection appeared to be transfusion in 30 patients, intravenous drug abuse in 16 patients and was unknown

A randomized controlled trial of interfe

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

✍ Saracco, G.; Rosina, F.; Cerenzia, M.R.Torrani; Lattore, V.; Chiandussi, L.; Gal 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 481 KB

Low-dose oral interferon-α in the treatm

Low-dose oral interferon-α in the treatment of chronic viral hepatitis type B: A double-blind, randomized, placebo-controlled, clinical trial

✍ Kiyomi Yasuda; Yasuo Ohashi; Takashi Matsushima; Hiromitsu Kumada; Kunihiko Hino 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 667 KB

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Interferon-α and zidovudine combination

Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial

✍ Harry L. A. Janssen; Luuk Berk; Rudolf A. Heijtink; Fiebo J. W. Ten Kate; Solko 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

Interferon-a therapy leads to HBeAg seroconversion in only one third of patients with chronic hepatitis B. In an attempt to increase the seroconversion rate, we investigated the combination of interferon-a and zidovudine in a subset of patients with presumably low response rates for interferon-a mon